Cleo Life Sciences

South San Francisco, United States· Est. 2004

Founded in 2004, Cleo Life Sciences offers a unique hybrid model combining strategic CMC consulting with hands-on, small-scale laboratory prototyping to de-risk and accelerate pharmaceutical development. The company leverages its founder's deep industry experience, having contributed to the CMC development of five commercial drugs and over 60 clinical-stage candidates. Its mission is to transform pharmaceutical development by enabling earlier, faster, and more efficient product and process development for its biopharma clients.

cleolifesciences.com

Private Company

Funding information not available

AI Company Overview

Technology Platform

An integrated CMC consulting and small-scale R&D prototyping platform that enables rapid, API-sparing formulation and process development for pharmaceuticals, accelerating tech transfer to GMP manufacturing.

Opportunities

Cleo is positioned to grow by serving the expanding universe of virtual and asset-centric biotechs that outsource development.

Opportunities include expanding service offerings into new therapeutic modalities (e.g., biologics, advanced delivery), forming strategic alliances with venture capital firms, and scaling its consultant network globally.

Risk Factors

Key risks include dependence on the founder's reputation and network, vulnerability to cyclical swings in biotech funding, and competition from larger CROs/CDMOs that could develop similar niche services.

The business model may also face scalability challenges.

Competitive Landscape

Cleo competes with large CROs (e.g., IQVIA), specialized CMC consultants, and CDMOs (e.g., Catalent). Its differentiation lies in its integrated model of high-touch consulting coupled with hands-on, small-scale prototyping lab work, specifically designed for early-stage, API-sparing development—a niche often underserved by larger players.

More companies in Drug Delivery & Formulation →More companies in United States →